Drug Research
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX's Probody® therapeutic platform and Regeneron's Veloci-Bi® bispecific antibody development platform.
The collaboration is strategically focused on applying CytomX's...
Drug Research
Australia Offers A Nasal Vaccine To Guard Against COVID-19
Researchers from Australia's Centenary Institute and the University of Sydney have created a novel nasal vaccination system that promotes strong lung resistance and tolerance against the SARS-CoV-2 coronavirus.
The newly developed vaccine strategy, which was successfully tested in mice and...
Drug Research
Big Pharma May Need To Report State Deals In WHO Crisis
Under new regulations that would oversee a pandemic agreement approved by the World Health Organization, which Reuters has reviewed, pharmaceutical companies might be required to disclose prices and agreements for any medications they produce to battle future global health...
Drug Research
In Britain, The ABPI Sets Out A Clear Antimicrobial Goal
The Association of the British Pharmaceutical Industry (ABPI) has reemphasized its message to the industry about the development of new antibiotics on the eve of World Antibiotic Awareness Week.
Antibiotic-resistant illnesses are thought to have caused 1.2 million deaths...
Drug Research
First Implanted Pump Uses Chemotherapy To Treat Brain Cancer
In a Phase I study that was recently published in the journal Lancet Oncology, it was shown that the first implantable pump system for individuals suffering from brain cancer could successfully kill reoccurring glioblastoma (GBM) tumour cells by continuously...
Drug Research
IGBA- 2022 WHO Biosimilar Roadmap Facilitates Accessibility
According to the new whitepaper Embracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline from the International Generic and Biosimilar Medicines Association (IGBA), the framework provides a fantastic opportunity to re-evaluate how regulatory standards can better progress...
Drug Research
GHIT Fund Invests ¥790M On Neglected Tropical Disease Items
Two neglected tropical illnesses, lymphatic filariasis and onchocerciasis, will receive a combined investment of about 790-million-yen ($5.3 million) from the Global Health Innovative Technology (GHIT) Fund in Japan.
The parasitic worms that cause lymphatic filariasis, also known as elephantiasis, and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















